×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PDSB – pds biotechnology corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PDSB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
01:22 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its price target lowered by analysts at HC Wainwright from $21.00 to $13.00. They now have a "buy" rating on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its price target lowered by analysts at HC Wainwright from $21.00 to $13.00. They now have a "buy" rating on the stock.
3/27
07:30 am
pdsb
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
Low
Report
PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update
3/25
08:00 am
pdsb
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
Medium
Report
PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference
3/23
08:58 am
pdsb
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]
Low
Report
PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts [Yahoo! Finance]
3/18
08:00 am
pdsb
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
Medium
Report
PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results
3/13
01:58 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Neutral
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
3/13
08:06 am
pdsb
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer [Yahoo! Finance]
Medium
Report
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer [Yahoo! Finance]
3/13
08:00 am
pdsb
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Low
Report
PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer
Date
Time
Symbol
Company Name
Action
%Chg
11/14/2024
08:00 am
pdsb
pds biotechnology corporation
IN-LINE
Report
-17.3%
pds biotechnology corporation
8/13/2024
08:00 am
pdsb
pds biotechnology corporation
BEAT
Report
0.0%
pds biotechnology corporation
5/15/2024
08:00 am
pdsb
pds biotechnology corporation
BEAT
Report
-11.4%
pds biotechnology corporation
Date
Time
Symbol
Headline
Impact
3/27
04:31 pm
pdsb
Form 10-K PDS Biotechnology Corp For: Dec 31
Low
Report
Form 10-K PDS Biotechnology Corp For: Dec 31
3/27
07:35 am
pdsb
Form 8-K PDS Biotechnology Corp For: Mar 27
Low
Report
Form 8-K PDS Biotechnology Corp For: Mar 27
3/13
08:05 am
pdsb
Form 8-K PDS Biotechnology Corp For: Mar 13
Low
Report
Form 8-K PDS Biotechnology Corp For: Mar 13
3/7
08:50 am
pdsb
Form 8-K PDS Biotechnology Corp For: Mar 07
High
Report
Form 8-K PDS Biotechnology Corp For: Mar 07
3/3
04:46 pm
pdsb
Form 4 PDS Biotechnology Corp For: Feb 28 Filed by: Freitag Gregory Gene
Medium
Report
Form 4 PDS Biotechnology Corp For: Feb 28 Filed by: Freitag Gregory Gene
3/3
04:45 pm
pdsb
Form 4 PDS Biotechnology Corp For: Feb 28 Filed by: Glover Stephen C.
Medium
Report
Form 4 PDS Biotechnology Corp For: Feb 28 Filed by: Glover Stephen C.
2/28
06:56 am
pdsb
Form 8-K PDS Biotechnology Corp For: Feb 26
Medium
Report
Form 8-K PDS Biotechnology Corp For: Feb 26
2/28
06:21 am
pdsb
Form 424B5 PDS Biotechnology Corp
Medium
Report
Form 424B5 PDS Biotechnology Corp
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/14
Q1/2019 3/31/2019 EPS 1.470 ZacksConsensus N/A ActVsEst N/A - N/A
41.4%
10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%
2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%
7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%
10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%
11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%
12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%
3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%
9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%
12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%
10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%
2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%
7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%
10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%
11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%
12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%
3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%
9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%
12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%
TOP News Decliners
2/11
PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock
-25.8%
9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%
12/17 Form S-1 PDS Biotechnology Corp -14.9%
3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%
12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%
2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%
11/14 Form S-8 PDS Biotechnology Corp -12.7%
4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%
11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%
6/4 Form S-8 PDS Biotechnology Corp -8.4%
9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%
12/17 Form S-1 PDS Biotechnology Corp -14.9%
3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%
12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%
2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%
11/14 Form S-8 PDS Biotechnology Corp -12.7%
4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%
11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%
6/4 Form S-8 PDS Biotechnology Corp -8.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: